Rexahn Pharmaceuticals, Inc.  

(Public, NYSEMKT:RNN)   Watch this stock  
Find more results for NYSEAMEX:RNN
-0.025 (-3.33%)
Jan 23 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.71 - 0.73
52 week 0.65 - 1.52
Open 0.71
Vol / Avg. 590,512.00/1.41M
Mkt cap 126.65M
P/E     -
Div/yield     -
EPS -0.11
Shares 178.25M
Beta 1.01
Inst. own 8%
Jan 14, 2015
Rexahn Pharmaceuticals Inc at EBD Biotech Showcase
Nov 24, 2014
Rexahn Pharmaceuticals Inc at Brean Capital's Life Sciences Summit Conference
Nov 13, 2014
Q3 2014 Rexahn Pharmaceuticals Inc Earnings Release
Nov 5, 2014
Rexahn Pharmaceuticals Inc at EBD Group BIO-Europe Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -20.19% -55.11%
Return on average equity -25.95% -85.74%
Employees 16 -
CDP Score - -


Suite 455, 15245 Shady Grove Road
United States - Map
+1-240-2685300 (Phone)
+1-240-2685310 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Rexahn Pharmaceuticals, Inc. is a development stage biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs. The Company�s focus is on three clinical stage drug candidates in active development, which are Archexin (Phase IIa completed); RX-3117 (Phase Ib initiated) and Supinoxin (RX-5902, Phase I trial initiated). In addition to these drug candidates, the Company has two clinical stage drug candidates for indications other than cancer: Serdaxin, for major depressive disorder; and Zoraxel, for sexual dysfunction. The Company also has three drug candidates in pre-clinical development: Archexin-Nano,for clinical benefits; RX-0047-Nano, for cancer cell survival, and RX-21101, for treatment of tumors. The Company is also working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.

Officers and directors

Chang H. Ahn Chairman of the Board, Chief Scientist
Age: 62
Bio & Compensation  - Reuters
Rakesh Soni President, Chief Operating Officer
Age: 58
Bio & Compensation  - Reuters
Peter D. Suzdak Ph.D. Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Tae Heum Jeong Chief Financial Officer, Secretary
Age: 43
Bio & Compensation  - Reuters
Richard J. Rodgers Director
Age: 47
Bio & Compensation  - Reuters
Charles G. Beever Independent Director
Age: 61
Bio & Compensation  - Reuters
Peter C. Brandt Independent Director
Age: 57
Bio & Compensation  - Reuters
Mark P. Carthy Independent Director
Age: 53
Bio & Compensation  - Reuters
Kwang Soo Cheong Independent Director
Age: 53
Bio & Compensation  - Reuters